Retroperitoneal liposarcoma is a rare, biologically heterogeneous tumor where complete macroscopic resection remains the mainstay of treatment, though local recurrence affects 60-70% of patients.
This review provides a comprehensive overview of the anatomy, natural history, diagnosis, and molecular pathology of retroperitoneal liposarcoma.
Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous tumor that present considerable challenges due to its size and deep location. As a consequence, the majority of patients with high-grade RLS will develop locally recurrent disease following surgery, and this constitutes the cause of death in most patients. Here, we review current insights and controversies regarding histology, molecular biology, extent of surgery, (neo)adjuvant treatment, and systemic treatment including novel targeted agents in RLS.
Matthyssens et al. (Tue,) conducted a review in Retroperitoneal liposarcoma. Retroperitoneal liposarcoma is a rare, biologically heterogeneous tumor where complete macroscopic resection remains the mainstay of treatment, though local recurrence affects 60-70% of patients.